Natco Pharma Ltd

- Natco Pharma currently has Rs. 116 crores of debt, primarily comprising Rs. 40 crores EPC credit (non-prepayable) and Rs. 76 crores foreign discounting (self-liquidating). - On a net debt basis, the company is effectively net cash with Rs. 2,004 crores in cash, listed shares, investments, and deposits. - The debt is mainly for working capital, and management is not very concerned about it. - There is no explicit mention of any planned new fundraising through debt or equity in the near future. - The management is contemplating acquisitions and may consider buybacks depending on acquisition outcomes but has not committed to new equity or debt raises. - CAPEX plans of about Rs. 300 to 350 crores annually are to be funded from existing resources. - Overall, no immediate plans for new fundraising via debt or equity have been indicated.

- The company plans a maintenance CAPEX of around Rs. 300 crores to Rs. 350 crores annually, mainly to maintain current operations and build orders. No large new site constructions are planned currently. (Page 18) - They are investing in complex generics, drug deliveries, oligopeptides, and CAR-T therapies as part of R&D and strategic innovation efforts. (Page 12) - Considering acquisitions primarily in the Rest of World (RoW) markets to strengthen the base business. No specific deals closed yet, but looking actively over the next few years. (Pages 5, 18) - Potential buyback considered if unable to close a large acquisition. (Page 4) - Exploring geographical expansion and niche filings along with acquisition as the three pillars for future growth. (Page 18)

- Targeting 15% to 20% top-line (sales/revenue) growth for FY '25 and beyond, with optimism to sustain this trajectory assuming no significant surprises. - Business aims to achieve approximately 20% profit growth alongside revenue growth. - Plans to triple the agrochemical business to Rs. 300 crores in the next 2-3 years. - Strategic focus on niche Para-IV filings to secure 2 to 3 successful first-to-file products in next 2 years. - Geographic expansion and acquisitions, particularly in Rest of World (RoW) markets, are key pillars to drive future growth. - Continued investment in complex generics, oligopeptides, drug delivery, and CAR-T therapies to fuel new growth avenues. - RoW business performing well with strong markets in Brazil, Canada, Egypt, and Saudi Arabia showing good growth potential. - Base domestic business expected to grow 8% to 10% with consistent secondary sales.

- Natco expects more than 20% growth in earnings/profits for FY '25 given no major surprises. - Management is optimistic about achieving 15%+ top-line growth and around 20% profit growth. - Stable margins are anticipated if the product mix holds up over the next 1-2 years. - The base business PAT is expected to be around Rs. 200-250 crores annually, consistent with earlier guidance. - Natco aims to reinvent growth through niche Para-IV filings, geographic expansion, and acquisitions. - The Agrochemical business targets a 3x growth to Rs. 300 crores in the next 3 years. - The company anticipates sustaining Rs. 400 crore PAT per quarter over 1-2 years with a 5% tolerance. - Overall, management’s approach is conservative with estimates, expecting surprises but focusing on steady growth.

- As per the transcript, Natco Pharma does not explicitly mention a current or expected order book or pending orders in exact figures. - The company highlighted strong ongoing business in Rest of World (RoW) markets with good orders from Egypt, Saudi Arabia, Brazil, and Canada. - Brazil direct exports and subsidiary exports are around $25-26 million annually; Canadian subsidiary sales near CAD 40 million. - The company is actively filing niche products, with ongoing confidence to file 2-3 first-to-file (FTF) products in coming years. - Business pipeline includes key product launches, including Semaglutide, Olaparib, Carfilzomib, Trabectedin, though litigations delay exact launch timelines. - The Crop Science division targets tripling business to Rs. 300 crores within 3 years, indicating expected growth and orders. - Working capital debt is effectively self-liquidating through receivables, reflecting healthy operational cash flow. No direct numeric order book data was disclosed.